HROW
VTRS
Viatris is pruning the garden
Viatris is selling Tyrvaya, its dry-eye spray, to Harrow in a deal worth $30 million upfront and up to $70 million more if sales milestones are hit. In plain English: Viatris is cashing out of one asset so it can spend more time on the stuff it actually wants to grow.
Why this matters
The company says the divestiture helps it focus on higher-potential areas like complex generics, transdermal products, and growth in Greater China. That’s the kind of strategic cleanup investors usually like — less clutter, more focus, fewer “maybe someday” projects sitting in the corner like a treadmill-turned-clothes-rack.
The earnings part of the story
Viatris also turned in a decent Q2:
- Adjusted EPS came in at 69 cents, topping the 60-cent consensus
- Revenue reached $3.756 billion, ahead of expectations
- Sales rose 5% year over year, helped by developed markets and strong growth in Greater China
And because good news apparently wasn’t enough, the company raised its 2026 outlook too. It nudged adjusted EPS guidance to $2.45-$2.49 from $2.33-$2.47, and lifted sales guidance to $14.55 billion-$14.95 billion from $14.45 billion-$14.95 billion.
So why did the stock fall?
Despite the better results and the shiny new guidance, VTRS shares were down about 4.2% Thursday afternoon. That suggests investors may be more focused on what Viatris is giving up — or just not ready to celebrate a turnaround until they see a few more quarters of this.
Big picture: Viatris is trying to look less like a sprawling leftover pharma bundle and more like a focused business with a plan. The market, naturally, is asking: great, but can you keep the momentum going?